Start free

Seaport Therapeutics, Inc. (SPTX) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 13, 2026.

Filings shown
17
Open-market buys
3
Open-market sells
0
Buys, 10b5-1 box not checked
3 of 3

Counts cover the 17 most recent Form 4 filings Tradune holds for SPTX (filed May 4 – Nov 13, 2026); the score below covers only the trailing 90 days (1 buy, 0 sells). SEC EDGAR Form 4 filings for SPTX last checked Nov 21, 2026, 09:00 UTC; the latest SPTX filing Tradune holds was filed Nov 13, 2026. This is not guaranteed to be the complete record — see SPTX's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 2 filings Tradune holds for SPTX filed Nov 4 – Nov 13, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Denice TorresDirector 1 0 5,000 — +$99,325

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

56/ 100

Net insider purchases
1 distinct buyer1 buy · 0 sell txofficer buying

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at SPTX

Insiders reported 3 open-market purchases of SPTX between May 4, 2026 and Nov 13, 2026, across 3 distinct buyers. The most recent purchase was reported by Denice Torres (Director) on Nov 3, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Daphne Zohar Chief Executive Officer · filed Nov 13, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Gift 100,000 — 1,094,001 −8.4% Nov 10, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

Denice Torres Director · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 5,000 $19.87 5,000 — Nov 3, 2026

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Robert J. Hombach Director · filed Jun 24, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 13,000 $18.14 13,000 (indirect) — Jun 22, 2026
PureTech Health plc 10% owner · filed May 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 12,736,014 — 13,038,493 (indirect) +4,211% May 4, 2026
Conversion of derivative Series B Preferred Stock 3,031,578 — — — May 4, 2026
Conversion of derivative 965,255 — 16,685,013 (indirect) +6.1% May 4, 2026
Conversion of derivative Series A-1 Preferred Stock 40,000,000 — — — May 4, 2026
Conversion of derivative 2,681,265 — 15,719,758 (indirect) +21% May 4, 2026
Conversion of derivative Series A-2 Preferred Stock 8,421,052 — — — May 4, 2026
James Healy Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 1,927,159 — 1,927,159 (indirect) — May 4, 2026
Conversion of derivative 804,379 — 2,731,538 (indirect) +42% May 4, 2026
Conversion of derivative Series A-2 Preferred Stock 6,052,631 — — — May 4, 2026
Conversion of derivative Series B Preferred Stock 2,526,315 — — — May 4, 2026
Lauren White Chief Financial Officer · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 6,702 — 6,702 (indirect) — May 4, 2026
Conversion of derivative Series B Preferred Stock 21,052 — — — May 4, 2026
Grant / award Stock Option (Right to Buy) 63,680 — — — Apr 30, 2026
Lana Gladstein General Counsel · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 33,515 — 33,515 — May 4, 2026
Conversion of derivative Series B Preferred Stock 105,263 — — — May 4, 2026
Grant / award Stock Option (Right to Buy) 63,680 — — — Apr 30, 2026
Michael Cunyuan Chen Chief Scientific Officer · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 3,351 — 3,351 — May 4, 2026
Conversion of derivative Series B Preferred Stock 10,526 — — — May 4, 2026
Grant / award Stock Option (Right to Buy) 63,680 — — — Apr 30, 2026
Denice Torres Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series B Preferred Stock 42,105 — — — May 4, 2026
Conversion of derivative 13,406 — 13,406 (indirect) — May 4, 2026
Grant / award Stock Option (Right to Buy) 12,258 — — — Apr 30, 2026
Steven M. Paul Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series B Preferred Stock 210,526 — — — May 4, 2026
Conversion of derivative 67,031 — 863,031 +8.4% May 4, 2026
Grant / award Stock Option (Right to Buy) 12,258 — — — Apr 30, 2026
Grant / award Stock Option (Right to Buy) 991,192 — — — Apr 30, 2026
Arch Venture Partners Xii, LLC 10% owner · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 2,513,686 — 2,513,686 (indirect) — May 4, 2026
Conversion of derivative 2,681,265 — 5,194,951 (indirect) +107% May 4, 2026
Open-market purchase 10b5-1 box not checked 1,100,000 $18.00 6,294,951 (indirect) +21% May 4, 2026
Conversion of derivative Series A-2 Preferred Stock 2,513,686 — — — May 4, 2026
Conversion of derivative Series B Preferred Stock 2,681,265 — — — May 4, 2026
Antony Loebel Chief Medical Officer · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 20,109 — 20,109 — May 4, 2026
Conversion of derivative Series B Preferred Stock 63,157 — — — May 4, 2026
Grant / award Stock Option (Right to Buy) 63,680 — — — Apr 30, 2026
Daphne Zohar Chief Executive Officer · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 271,813 — — — Apr 30, 2026
Grant / award Stock Option (Right to Buy) 1,486,786 — — — Apr 30, 2026
David E. Wheadon Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 12,258 — — — Apr 30, 2026
Sandra E. Peterson Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 12,258 — — — Apr 30, 2026
Robert J. Hombach Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 12,258 — — — Apr 30, 2026
Sharon Mates Director · filed May 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 49,033 — — — Apr 30, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to SPTX's (Nov 13, 2026).

Frequently asked about SPTX insider activity

How many insiders bought SPTX stock in these Form 4 filings?

3 distinct insiders at Seaport Therapeutics, Inc. reported 3 open-market purchases (Form 4 code P) of SPTX shares between May 4, 2026 and Nov 13, 2026, the most recent filed by Denice Torres (Director) on Nov 3, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for SPTX?

The most recent Form 4 on this page was filed by Daphne Zohar (Chief Executive Officer) on Nov 13, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market SPTX insider purchase shown?

The largest open-market purchase among the filings shown was 1,100,000 SPTX shares at $18.00 (about $19,800,000) by Arch Venture Partners Xii, LLC (10% owner) on May 4, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent SPTX insider purchases have the Form 4 10b5-1 box checked?

No. All 3 SPTX open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Denice Torres (Director) on Nov 3, 2026, 5,000 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for SPTX — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.